502 related articles for article (PubMed ID: 22211810)
1. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
2. Newcastle disease virus as an oncolytic agent.
Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
[TBL] [Abstract][Full Text] [Related]
3. [Progress in using Newcastle disease virus for tumor therapy: a review].
Wu Y; Hao J; Li D
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
[TBL] [Abstract][Full Text] [Related]
4. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
5. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
[TBL] [Abstract][Full Text] [Related]
6. Apoptin enhances the oncolytic properties of Newcastle disease virus.
Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S
Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658
[TBL] [Abstract][Full Text] [Related]
7. Safety and clinical usage of newcastle disease virus in cancer therapy.
Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
Huang Z; Liu M; Huang Y
Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
[TBL] [Abstract][Full Text] [Related]
9. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
10. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.
Vijayakumar G; Zamarin D
Methods Mol Biol; 2020; 2058():133-154. PubMed ID: 31486036
[TBL] [Abstract][Full Text] [Related]
11. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
13. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
14. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
Kalyanasundram J; Hamid A; Yusoff K; Chia SL
Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
[TBL] [Abstract][Full Text] [Related]
16. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Meng Q; He J; Zhong L; Zhao Y
Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
[TBL] [Abstract][Full Text] [Related]
17. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
[TBL] [Abstract][Full Text] [Related]
18. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain.
Balogh A; Bátor J; Markó L; Németh M; Pap M; Sétáló G; Müller DN; Csatary LK; Szeberényi J
Virus Res; 2014 Jun; 185():10-22. PubMed ID: 24637408
[TBL] [Abstract][Full Text] [Related]
20. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
